MedTrace Logo

ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

NCT07247097 · Status: NOT_YET_RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 160

Last updated 2025-11-25

No results posted yet for this study

Summary

This research study is being done to compare the efficacy and safety of the combination of elranatamab, lenalidomide, bortezomib, dexamethasone versus the combination of daratumumab, lenalidomide, bortezomib, dexamethasone for patients with newly diagnosed, transplant ineligible/deferred multiple myeloma.

Conditions

  • Multiple Myeloma
  • Newly Diagnosed Multiple Myeloma
  • Transplant Ineligible
  • Newly Diagnosed Multiple Myeloma (NDMM)

Interventions

DRUG

Elranatamab (PF-06863135)

Elranatamab is a bispecific IgG2 kappa monoclonal antibody.

DRUG

Daratumumab and Hyaluronidase-fihj

Daratumumab is an immunoglobulin G1 kappa human monoclonal antibody against CD38 antigen.

DRUG

Lenalidomide

Lenalidomide is a thalidomide analogue and an immunomodulatory agent with antiangiogenic properties.

DRUG

Bortezomib for Injection

Bortezomib for injection is a small molecule proteosome inhibitor.

DRUG

Dexamethasone

Dexamethasone is a synthetic adrenocortical steroid.

Sponsors & Collaborators

  • Pfizer

    collaborator INDUSTRY

  • Massachusetts General Hospital

    lead OTHER

Principal Investigators

  • Andrew Yee, MD · Massachusetts General Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-04-15
Primary Completion
2030-12-01
Completion
2035-12-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07247097 on ClinicalTrials.gov